SS-31 peptide half-life is roughly two hours in plasma, so dosing frequency, route, and formulation all matter. Here's what current research shows.
In human plasma, the SS-31 peptide half-life is short, averaging roughly 2 hours after an intravenous dose, with similar or slightly longer values reported for subcutaneous administration. SS-31, also known as elamipretide, clears from circulation quickly, so research protocols usually rely on frequent dosing or a continuous infusion to keep blood levels steady. The exact number shifts with the route of administration, the formulation, and the individual.
What Is SS-31 (Elamipretide)?
SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to concentrate inside mitochondria, the energy-producing structures in cells. It binds to cardiolipin on the inner mitochondrial membrane, an interaction researchers study for its effects on oxidative stress and cellular energy production.
Scientists have examined elamipretide in conditions linked to mitochondrial dysfunction, including ischemia-reperfusion injury, heart failure, Barth syndrome, and primary mitochondrial myopathy. Elamipretide is not FDA-approved for any human use in the United States as of this writing.
Reported Half-Life Values for SS-31
Half-life describes the time it takes for the body to eliminate half of a drug. Across published studies, SS-31 shows a consistently short plasma half-life, usually measured in hours rather than days.
| Route | Reported half-life | Notes |
|---|---|---|
| Intravenous (IV) infusion | About 2 hours | Terminal half-life reported in healthy adult volunteers |
| Subcutaneous (SC) injection | About 2 to 3 hours | Slower absorption from tissue; bioavailability is incomplete |
| Animal models (IV) | About 1 to 2 hours | Rapid distribution into tissues, especially kidney and liver |
These numbers are approximate. Different assays, sampling schedules, and dose levels can produce slightly different results, so the ss 31 half life quoted online should be treated as a range rather than a fixed constant.
Why a Short Half-Life Shapes Dosing
A two-hour half-life means plasma levels fall by half every two hours after a dose. Steady state is generally reached after about four to five half-lives, which for SS-31 works out to roughly 8 to 10 hours.
In clinical research, that short window has pushed investigators toward:
- Continuous IV infusions that deliver a steady dose over several hours.
- Daily or twice-daily subcutaneous injections.
- Higher doses to offset rapid clearance between administrations.
When people compare ss-31 peptide dosage schedules or look up an ss-31 peptide dosing protocol, they quickly notice that frequent administration is built into the design for exactly this reason. Stretching the interval between doses can let blood levels fall well below the target range.
What Can Change SS-31 Half-Life?
Several practical factors can shift how long SS-31 stays in circulation:
- Route of administration: IV delivery produces the sharpest peak and fastest decline, while subcutaneous absorption flattens the curve.
- Formulation and reconstitution: How a lyophilized powder is dissolved, its pH, and its concentration can affect absorption and stability.
- Kidney and liver function: Peptides are cleared partly by these organs, so impaired function may prolong exposure.
- Body composition and blood flow: Injection site and circulation influence how quickly a dose reaches the bloodstream.
- Storage: Improper temperature or light exposure can degrade the peptide before it is ever used.
No single factor explains every difference between studies, and human pharmacokinetic data remain limited.
Reported Benefits and Side Effects in Research
Study results for elamipretide have been mixed. Some early trials reported improvements in exercise tolerance or mitochondrial function markers, while a larger trial in primary mitochondrial myopathy did not meet its primary endpoint.
Commonly reported ss-31 peptide side effects in trials include injection site reactions, headache, nausea, and diarrhea. Serious adverse events have been uncommon, but the overall safety database is still small, and most positive findings come from small or early-stage studies.
Research Use vs. Real-World Products
SS-31 is sold online as a research chemical, often labeled for laboratory use only. Products marketed that way are not verified for purity, sterility, or identity by the FDA, and dosing details found in a typical ss-31 peptide review may not match the conditions used in clinical trials.
Bodybuilding and biohacking communities sometimes discuss SS-31 for recovery and energy, but controlled human evidence for those uses is thin. Anyone considering it should speak with a healthcare professional, especially if they take prescription medications or have kidney, liver, or heart conditions.
Key Takeaways on SS-31 Half-Life
- SS-31 (elamipretide) has a plasma half-life of roughly 2 hours after IV administration.
- Subcutaneous dosing produces a similar or slightly longer half-life, often around 2 to 3 hours.
- Steady state is reached in about 8 to 10 hours, which is why research protocols use frequent or continuous dosing.
- Elamipretide is not FDA-approved for human use in the United States.
- Half-life values vary by study, route, formulation, and individual physiology.
Frequently Asked Questions
How long does SS-31 stay in your system?
SS-31 has a plasma half-life of about 2 hours after an IV dose and roughly 2 to 3 hours after a subcutaneous injection. Most of a single dose is cleared within about 8 to 12 hours, though trace amounts may linger longer in tissue. Individual physiology and the testing method used can change these estimates.
Is SS-31 the same as elamipretide?
Yes. SS-31 is the research name for elamipretide, which has also been studied under the names MTP-131 and Bendavia. It is a mitochondria-targeted tetrapeptide investigated for conditions involving mitochondrial dysfunction. Elamipretide is not FDA-approved for human use.
Is SS-31 FDA-approved?
No. As of this writing, elamipretide (SS-31) has not received FDA approval for any human indication. It is available only through clinical trials as an investigational drug or as a research chemical sold for laboratory use, which is not intended for human consumption.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.